Class Action Lawsuit Filed Against Medpace Holdings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy MEDP?
Source: Globenewswire
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Medpace Holdings (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, allowing potential lead plaintiffs to apply by June 8, 2026, indicating the legal proceedings are underway.
- Compensation Structure: Investors participating in the lawsuit may receive compensation without any out-of-pocket costs, providing a risk-free legal avenue for investors to seek recovery of losses, thereby enhancing investor confidence in the process.
- Allegations of Misrepresentation: The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rates during the class period, leading investors to have overly optimistic growth expectations, which could adversely affect the company's market reputation.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and influence in handling similar cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 528.440
Low
462.00
Averages
569.17
High
660.00
Current: 528.440
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medpace to Announce Q1 Earnings on April 22
- Earnings Announcement Schedule: Medpace (MEDP) is set to release its Q1 2023 earnings on April 22 after market close, with consensus EPS estimates at $3.96, reflecting a 23.7% year-over-year increase, and revenue estimates at $697.63 million, up 24.9%, indicating strong growth potential.
- Performance Beat Record: Over the past two years, Medpace has surpassed EPS estimates 75% of the time and revenue estimates 63% of the time, showcasing the company's strong performance against analyst expectations, which bolsters investor confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw one upward and one downward revision, while revenue estimates experienced five upward revisions with no downward adjustments, reflecting a positive market outlook for Medpace's future performance, potentially driving stock price increases.
- Future Growth Outlook: Medpace anticipates revenue growth of up to 12.8% in 2026, primarily due to backlog normalization and shifts in metabolic trials, demonstrating the company's strategic capability to adapt to market changes and seize growth opportunities.
See More
Medpace Holdings Class Action Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Medpace made false and misleading statements during the class period, concealing the true cancellation rates, which led investors to have overly optimistic growth expectations that could not sustain a 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS for the number of settlements in 2017, showcasing its strong capabilities in this field.
- How to Participate: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on joining the class action, with no upfront fees required, ensuring the protection of investors' rights.
See More
Medpace Faces Class Action Lawsuit Allegations
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces that investors who purchased Medpace Holdings Inc. (NASDAQ:MEDP) stock between April 22, 2025, and February 9, 2026, can seek lead plaintiff status by June 8, 2026, indicating strong investor concern over the company's financial transparency.
- Financial Misconduct Allegations: The lawsuit alleges that Medpace and its executives violated the Securities Exchange Act of 1934 by overstating the projected book-to-bill ratio for Q4 2025, leading to investor misconceptions about the company's performance, which could adversely affect shareholder confidence and market performance.
- Stock Price Volatility: Following the release of Q4 2025 earnings on February 9, 2026, which revealed a book-to-bill ratio of only 1.04, significantly below expectations, Medpace's stock price plummeted nearly 16%, reflecting market disappointment and a crisis of trust in the company.
- Legal Process Overview: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Medpace stock during the class period can apply to be the lead plaintiff, who will represent other investors in the lawsuit, emphasizing the critical role of investors in legal proceedings.
See More
Medpace Faces Class Action Lawsuit Impacting Stock Price
- Class Action Initiation: Pomerantz LLP has filed a class action lawsuit against Medpace Holdings, alleging that the company and certain officers may have engaged in securities fraud or other unlawful business practices, which could have long-term negative implications for the company's reputation and stock price.
- Significant Stock Drop: Following the release of its Q4 2025 earnings on February 9, 2026, which revealed a book-to-bill ratio of 1.04, significantly below guidance, Medpace's stock plummeted by 15.9% to close at $446.05, reflecting market disappointment in the company's performance.
- Investor Action Deadline: Investors are advised to apply by June 8, 2026, to be appointed as Lead Plaintiff in the class action, indicating that the lawsuit may attract a large number of affected investors, further exacerbating the legal risks faced by the company.
- Law Firm Background: Pomerantz LLP is a prominent class action law firm specializing in corporate and securities litigation, with over 85 years of experience, suggesting that this case may draw significant legal scrutiny and potential liability for Medpace.
See More
Medpace Holdings Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Medpace Holdings (NASDAQ:MEDP) for violations of securities laws during the period from April 22, 2025, to February 9, 2026.
- False Statements Allegation: The complaint alleges that Medpace made false and misleading statements that artificially inflated its stock price, resulting in investor losses once the truth was revealed to the market.
- Investor Action Call: Affected investors are encouraged to contact the Schall Law Firm before June 5, 2026, to participate in the lawsuit and seek compensation, highlighting the firm's commitment to shareholder rights.
- Legal Process Status: The class action has not yet been certified, meaning investors are not currently represented by an attorney, underscoring the importance of timely action to protect their rights.
See More
Faruqi & Faruqi Encourages Medpace Investors to Reach Out
- Legal Investigation: Faruq & Faruqi, LLP is investigating potential claims against Medpace Holdings, Inc., particularly for investors who purchased or acquired securities between April 22, 2025, and February 9, 2026, highlighting concerns for investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to discuss legal options, demonstrating a commitment to client service.
- Class Action Deadline: The firm reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against Medpace is June 8, 2026, emphasizing the urgency and importance of legal proceedings.
- Securities Law Firm Background: As a leading national securities law firm, Faruq & Faruqi's investigation underscores its expertise and influence in protecting investor rights, which may negatively impact Medpace's stock price and reputation.
See More
Medpace to Announce Q1 Earnings on April 22
- Earnings Announcement Schedule: Medpace (MEDP) is set to release its Q1 2023 earnings on April 22 after market close, with consensus EPS estimates at $3.96, reflecting a 23.7% year-over-year increase, and revenue estimates at $697.63 million, up 24.9%, indicating strong growth potential.
- Performance Beat Record: Over the past two years, Medpace has surpassed EPS estimates 75% of the time and revenue estimates 63% of the time, showcasing the company's strong performance against analyst expectations, which bolsters investor confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw one upward and one downward revision, while revenue estimates experienced five upward revisions with no downward adjustments, reflecting a positive market outlook for Medpace's future performance, potentially driving stock price increases.
- Future Growth Outlook: Medpace anticipates revenue growth of up to 12.8% in 2026, primarily due to backlog normalization and shifts in metabolic trials, demonstrating the company's strategic capability to adapt to market changes and seize growth opportunities.
See More
Medpace Holdings Class Action Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Medpace made false and misleading statements during the class period, concealing the true cancellation rates, which led investors to have overly optimistic growth expectations that could not sustain a 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS for the number of settlements in 2017, showcasing its strong capabilities in this field.
- How to Participate: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on joining the class action, with no upfront fees required, ensuring the protection of investors' rights.
See More
Medpace Faces Class Action Lawsuit Allegations
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces that investors who purchased Medpace Holdings Inc. (NASDAQ:MEDP) stock between April 22, 2025, and February 9, 2026, can seek lead plaintiff status by June 8, 2026, indicating strong investor concern over the company's financial transparency.
- Financial Misconduct Allegations: The lawsuit alleges that Medpace and its executives violated the Securities Exchange Act of 1934 by overstating the projected book-to-bill ratio for Q4 2025, leading to investor misconceptions about the company's performance, which could adversely affect shareholder confidence and market performance.
- Stock Price Volatility: Following the release of Q4 2025 earnings on February 9, 2026, which revealed a book-to-bill ratio of only 1.04, significantly below expectations, Medpace's stock price plummeted nearly 16%, reflecting market disappointment and a crisis of trust in the company.
- Legal Process Overview: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Medpace stock during the class period can apply to be the lead plaintiff, who will represent other investors in the lawsuit, emphasizing the critical role of investors in legal proceedings.
See More
Medpace Faces Class Action Lawsuit Impacting Stock Price
- Class Action Initiation: Pomerantz LLP has filed a class action lawsuit against Medpace Holdings, alleging that the company and certain officers may have engaged in securities fraud or other unlawful business practices, which could have long-term negative implications for the company's reputation and stock price.
- Significant Stock Drop: Following the release of its Q4 2025 earnings on February 9, 2026, which revealed a book-to-bill ratio of 1.04, significantly below guidance, Medpace's stock plummeted by 15.9% to close at $446.05, reflecting market disappointment in the company's performance.
- Investor Action Deadline: Investors are advised to apply by June 8, 2026, to be appointed as Lead Plaintiff in the class action, indicating that the lawsuit may attract a large number of affected investors, further exacerbating the legal risks faced by the company.
- Law Firm Background: Pomerantz LLP is a prominent class action law firm specializing in corporate and securities litigation, with over 85 years of experience, suggesting that this case may draw significant legal scrutiny and potential liability for Medpace.
See More
Medpace Holdings Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Medpace Holdings (NASDAQ:MEDP) for violations of securities laws during the period from April 22, 2025, to February 9, 2026.
- False Statements Allegation: The complaint alleges that Medpace made false and misleading statements that artificially inflated its stock price, resulting in investor losses once the truth was revealed to the market.
- Investor Action Call: Affected investors are encouraged to contact the Schall Law Firm before June 5, 2026, to participate in the lawsuit and seek compensation, highlighting the firm's commitment to shareholder rights.
- Legal Process Status: The class action has not yet been certified, meaning investors are not currently represented by an attorney, underscoring the importance of timely action to protect their rights.
See More
Faruqi & Faruqi Encourages Medpace Investors to Reach Out
- Legal Investigation: Faruq & Faruqi, LLP is investigating potential claims against Medpace Holdings, Inc., particularly for investors who purchased or acquired securities between April 22, 2025, and February 9, 2026, highlighting concerns for investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to discuss legal options, demonstrating a commitment to client service.
- Class Action Deadline: The firm reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against Medpace is June 8, 2026, emphasizing the urgency and importance of legal proceedings.
- Securities Law Firm Background: As a leading national securities law firm, Faruq & Faruqi's investigation underscores its expertise and influence in protecting investor rights, which may negatively impact Medpace's stock price and reputation.
See More
